52094-70-9

Basic information

• Product Name: 7,6-benzo-1,3-diazaspiro(4,5)decane-2,4-dione
• Synonyms: 7,6-benzo-1,3-diazaspiro(4,5)decane-2,4-dione;Tetrantoin;3',4'-Dihydrospiro[imidazolidine-4,2'(1'H)-naphthalene]-2,5-dione;S.2-676;Spiro[imidazolidine-4,2'-tetralin]-2,5-dione;Spiro[tetralin-2,4'-imidazolidine]-2',5'-dione;7,8-Benzo-1,3-diazaspiro(4.5)decane-2,4-dione;Benzo(G)quinazoline-2,4(1H,3H)-dione (8ci)
• CAS NO: 52094-70-9
• Molecular Formula: C₁₂H₁₂N₂O₂
• Molecular Weight: 216.239
• EINECS: 257-658-9
• Mol File: 52094-70-9.mol

Chemical Properties

• Melting Point: 267-268°
• Boiling Point: °Cat760mmHg
• Flash Point: °C
• Appearance: /
• Density: 1.34g/cm³
• Refractive Index: 1.641
• CAS DataBase Reference: 7,6-benzo-1,3-diazaspiro(4,5)decane-2,4-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 7,6-benzo-1,3-diazaspiro(4,5)decane-2,4-dione(52094-70-9)
• EPA Substance Registry System: 7,6-benzo-1,3-diazaspiro(4,5)decane-2,4-dione(52094-70-9)

Safety Data

• Hazardous Substances Data: 52094-70-9(Hazardous Substances Data)

Usage

InChI:InChI=1/C12H12N2O2/c15-10-12(14-11(16)13-10)6-5-8-3-1-2-4-9(8)7-12/h1-4H,5-7H2,(H2,13,14,15,16)

Upstream product

• 151-50-8 potassium cyanide 
• 530-93-8 1,2,3,4-tetrahydronaphthalen-2-one 
• 506-87-6 ammonium carbonate 
• 773837-37-9 sodium cyanide 
• 99842-56-5 2-hydroxy-1,2,3,4-tetrahydronaphthalene-2-carbonitrile 
• 136370-80-4 2-(trimethylsilanyloxy)-1,2,3,4-tetrahydronaphthalene-2-carbonitrile 

Downstream Products

• 6331-63-1 2-amino-1,2,3,4-tetrahydro-naphthalene-2-carboxylic acid 
• 109402-15-5 1-methyl-3',4'-dihydro-1'H-spiro[imidazolidine-4,2'-naphthalene]-2,5-dione 
• 905278-25-3 3-benzylspiro(imidazolidine-5,2'-tetraline)-2,4-dione 
• 264149-58-8 1,3-dibenzylspiro(imidazolidine-5,2'-tetraline)-2,4-dione 
• 905278-35-5 1,3-dibenzyl-4-hydroxyspiro(imidazolidine-5,2'-tetraline)-2-one 
• 104974-44-9 (R)-2-Amino-1,2,3,4-tetrahydronaphthalene-2-carboxylic acid 
• 104974-44-9 (S)-2-amino-1,2,3,4-tetrahydronaphthalene-2-carboxylic acid 
• 144646-18-4 2-benzamido-1,2,3,4-tetrahydronaphthalene-2-carboxylic acid 
• 144646-53-7 (R)-2-amino-1,2,3,4-tetrahydronaphthalene-2-carboxylic acid hydrochloride 
• 144646-42-4 N^2.2-<(R)-2-benzamido-1,2,3,4-tetrahydronaphthalene-2-carbonyl>-L-phenylalanyl-L-phenylalanine N^1.3,N^1.3-(tetramethylene)amide 
• 144731-96-4 N^2.2-<(S)-2-benzamido-1,2,3,4-tetrahydronaphthalene-2-carbonyl>-L-phenylalanyl-L-phenylalanine N^1.3,N^1.3-(tetramethylene)amide 
• 144646-27-5 methyl 2-benzamido-1,2,3,4-tetrahydronaphthalene-2-carboxylate 
• 144732-05-8 (R)-methyl 2-benzamido-1,2,3,4-tetrahydronaphthalene-2-carboxylate 
• 144732-06-9 (S)-methyl 2-benzamido-1,2,3,4-tetrahydronaphthalene-2-carboxylate 

Relevant articles and documents

Spiro structural restrictive 5-methylmorpholine-3-amine-2-oxazolidone antigen, spiro structural restrictive 5-methylmorpholine-3-amine-2-oxazolidone antibody, method for preparing spiro structural restrictive 5-methylmorpholine-3-amine-2-oxazolidone antigen and application of spiro structural restrictive 5-methylmorpholine-3-amine-2-oxazolidone antigen and spiro structural restrictive 5-methylmorpholine-3-amine-2-oxazolidone antibody

The invention discloses a spiro structural restrictive 5-methylmorpholine-3-amine-2-oxazolidone antigen, a spiro structural restrictive 5-methylmorpholine-3-amine-2-oxazolidone antibody, a method forpreparing the spiro structural restrictive 5-methylmorpholine-3-amine-2-oxazolidone antigen and application of the spiro structural restrictive 5-methylmorpholine-3-amine-2-oxazolidone antigen and thespiro structural restrictive 5-methylmorpholine-3-amine-2-oxazolidone antibody. The method includes modifying 5-methylmorpholine-3-amine-2-oxazolidone molecular structures; synthesizing 5-methylmorpholine-3-amine-2-oxazolidone haptens with spiro structures; preparing the 5-methylmorpholine-3-amine-2-oxazolidone artificial antigen and the 5-methylmorpholine-3-amine-2-oxazolidone antibody on the basis of the 5-methylmorpholine-3-amine-2-oxazolidone haptens. The spiro structural restrictive 5-methylmorpholine-3-amine-2-oxazolidone antigen, the spiro structural restrictive 5-methylmorpholine-3-amine-2-oxazolidone antibody, the method and the application have the advantages that the spiro structural restrictive 5-methylmorpholine-3-amine-2-oxazolidone antigen and the spiro structural restrictive 5-methylmorpholine-3-amine-2-oxazolidone antibody are high in titer and detection efficiency; the shortcomings of long periods, high specialty and cost, unsuitability for field large-scale quick detection and the like of the traditional instrumental processes can be overcome; procedures for synthesizing the antigen and the antibody are simple and are low in cost, enzyme-linked immunoassay quickdetection tools which are low in cost, high in detection efficiency and easy and convenient to operate can be developed, the foundation can be laid, and the spiro structural restrictive 5-methylmorpholine-3-amine-2-oxazolidone antigen, the spiro structural restrictive 5-methylmorpholine-3-amine-2-oxazolidone antibody and the method have excellent application prospects.

Continuous Synthesis of Hydantoins: Intensifying the Bucherer-Bergs Reaction

A continuous Bucherer-Bergs hydantoin synthesis utilizing intensified conditions is reported. The methodology is characterized by a two-feed flow approach to independently feed the organic substrate and the aqueous reagent solution. The increased interfacial area of the biphasic reaction mixture and the lack of headspace enabled almost quantitative conversions within ca. 30 minutes at 120 °C and 20 bar even for unpolar starting materials. In addition, a selective N(3)-monoalkylation of the resulting heterocycles under batch microwave conditions is reported yielding potential acetylcholinesterase inhibitors.

AMIDOALKYLPIPERAZINYL DERIVATIVES FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES

The invention relates to novel amidoalkylpiperazinyl derivatives of tricyclic heterocyclic systems of general formula (I), wherein Z represents -NH- and X represents -S-, or Z represents -S- and X represents >C=C1 represents H or -CH3, R6 and R7 both represent H, n is an integer from 0 to 4 inclusive, G represents a cyclic amide or imide moiety, and optical isomers, geometric isomers, and pharmaceutically acceptable salts thereof. The compounds may be useful for the treatment and/or prevention of the central nervous system disorders.

Candida antarctica Lipase B in a chemoenzymatic route to cyclic α-quaternary α-amino acid enantiomers

Kinetic resolution of three cyclic quaternary ethyl 1-amino-2,3-dihydro-1H- indene-1-carboxylates and both 1- and 2-amino-1,2,3,4-tetrahydronaphthalene analogues have been studied. Interesterification with butyl butanoate and Candida antarctica lipase B accomplished the task. The enantiomers of all 1-amino analogues reacted with excellent enantioselectivity (enantiomeric ratio er greater than 200), whereas the 2-amino analogue was not enantioselective (er = 4). Amino acid enantiomers were finally obtained as their respective hydrochlorides with almost maximum theoretical yields. For the first time, a lipase enzyme was effectively used in the kinetic resolution of cyclic α-quaternary α-amino esters. Copyright

General and versatile entry to 4,5-fused polycyclic imidazolones systems. Use of the tandem transposition/π-cyclization of N-acyliminium species

A simple and efficient methodology for the synthesis of 4,5-fused imidazolidin-2-ones from bicyclic and tricyclic ketones in a four-step sequence was described, by successive spirohydantoin Bucherer-Berg formation, mono- and dialkylation of the nitrogen atom of the hydantoin ring, regioselective reduction of one carbonyl function, and cationic cyclization associated with ring expansion. The key step of this sequential reaction was based on a tandem transposition/intramolecular amidoalkylation of cyclic spiro-N-acyliminium species. The process seems to be easy, general, regiospecific, resulted in the formation of polyheterocyclic systems containing an imidazolidin-2-one nucleus in good to excellent yields (67-99%), and is compatible with a large-scale production (up to 3 g of product 14, for example). Also, this method allows the preparation of the novel heterocycles 14 and 15 that have pharmaceutically interesting profiles, which are not accessible through short current synthetic methods. Finally, products 15 bear a secondary amide function crucial for further transformations, including the introduction of various pharmacophore groups either at the C or the N atoms of the imidazole ring.

TETRALINE DERIVATIVES AS GHRELIN RECEPTOR MODULATORS

The present invention is related to compounds of formula (I), or a therapeutically suitable salt or prodrug thereof, the preparation of the compounds, compositions containing the compounds and the use of the compounds in the prevention or treatment of disorders regulated by ghrelin including anorexia, cancer cachexia, eating disorders, age-related decline in body composition, weight gain, obesity, and diabetes mellitus.